Tba 200fr neo

Peripheral venous blood samples were collected within 30 min of admission. The plasma glucose and potassium levels were measured using a TBA-200FR Neo (Toshiba Medical Systems, Tokyo, Japan). There was no equipment replacement during the study period. The reference range of the plasma glucose level in our institutions was 70–99 mg/dl, and the reference range of the plasma potassium level was 3.5–5.5 mmol/l. The patients with hypokalemia were classified as mild hypokalemia (3.1–3.4 mmol/l), moderate hypokalemia (2.5–3.0 mmol/l), and sever hypokalemia (<2.5 mmol/l).
Patients demographic characteristics, clinical features, and laboratory data were collected. Clinical severity of aSAH on ED admission was evaluated according to the HH scale. We defined severe aSAH as HH scale score 4–5. The primary endpoint of interest was death within 3 months. The secondary endpoint was poor functional outcome at 3 months following ED admission; poor functional outcome was assessed using the modified Rankin scale (mRS score of 3–6). To assess the outcomes after 3 months, a review of the medical records or a telephone interview were conducted by a physician who was blinded to the clinical information.

Blood samples were obtained from the right ventricle, and the levels of AST, ALT and ALP were measured by an autoanalyzer (TBA-200FR NEO; Toshiba Medical Systems Corp., Tokyo, Japan).

Plasma samples were collected within 49 h of stroke onset to measure the levels of total Hcy and folate. Whole blood was collected from patients 12 h after their last meal using tubes containing anticoagulants. Tubes were centrifuged for 15 min at 1000× g to separate the plasma. Total plasma Hcy concentrations were measured using a fluorescent polarizing immunoassay with an IMx system (Abbott Laboratories, Chicago, IL, USA), while plasma folate concentrations were measured using an immunoassay kit (ACS 180; Bayer, Tarrytown, NY, USA). Levels of high-density lipoprotein-cholesterol (HDL-C) were determined using enzymatic colorimetric methods with commercial reagent sets (TBA 200FR NEO, Toshiba Medical Systems, Tokyo, Japan).

Anthropometric measurements included the body mass index (BMI). Systolic and diastolic blood pressures were measured in the seated position after 10 min of rest. For measurements of physiological parameters, 3 mL blood samples were obtained after overnight fasting. Plasma glucose levels were measured in duplicate by the hexokinase method, adapted to an automated analyzer (TBA 200FR NEO, Toshiba Medical Systems, Tokyo, Japan). Levels of high-density lipoprotein cholesterol (HDL-C) were determined by enzymatic colorimetric methods, using commercial reagent sets (Toshiba Medical Systems). Plasma homocysteine (Hcy) concentrations were measured by fluorescent polarizing immunoassay (FPIA) with the IMx automated immunohistochemistry system (Abbott Laboratories, Chicago, IL, USA). Plasma concentrations of fatty acids (FA) were determined using a radioassay kit (ACS:180, Bayer, Tarrytown, NY, USA).

Anthropometric measurements included BMI. Systolic and diastolic blood pressures of subjects were measured in the seated position after 10 min of rest. For measurements of physiological parameters, 3-ml samples of blood were obtained after fasting overnight. Plasma glucose was determined in duplicate using the hexokinase method adapted for an automated analyzer (TBA 200FR NEO, Toshiba Medical Systems, Tokyo, Japan). Levels of TG and HDL-C were determined by enzymatic colorimetric methods using commercial reagent sets (Toshiba Medical Systems). The concentration of Hcy in the plasma was measured by fluorescence polarization immunoassay (FPIA) with the IMx automated analyzer (Abbott Laboratories, Chicago, IL, USA). The plasma concentration of FA was determined using a radioassay kit (ACS:180, Bayer, Tarrytown, NY, USA).

After at least 12 h of overnight fasting, blood samples were drawn as the routine GME protocol and were centrifuged within one hour. The serum samples were stored at −80 °C until use. Total cholesterol, low-density lipoprotein cholesterol, HDL-C, and triglycerides were measured by enzymatic reagents (Kyowa Kirin Co., Ltd., Tokyo, Japan) on a chemistry analyzer (TBA-200FR NEO, Toshiba Medical System Co., Tokyo, Japan). Low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald formula: LDL-C = Total cholesterol-(triglycerides/5)-HDL-C. Serum adiponectin was measured by Randox immunoturbidimetric adiponectin assay (Randox Laboratories Ltd., Crumlin, UK), according to the manufacturer’s protocol [22 ].